CSIR-Central Institute of Medicinal and Aromatic Plants (CSIR-CIMAP), P.O. CIMAP, Kukrail Picnic Spot Road, Lucknow 226 015, U.P., India.
Endocrinology Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, U.P., India.
Bioorg Med Chem. 2021 Jul 15;42:116252. doi: 10.1016/j.bmc.2021.116252. Epub 2021 Jun 5.
Breast cancer is the second leading cause of cancer deaths in women with significant morbidity and mortality. Present study describes design, synthesis and detailed pharmacology of indole derivatives exhibiting remarkable broad spectrum antiproliferative activity against breast cancer cells. Detailed mechanistic evaluations confirmed induction of G0/G1 arrest, apoptosis induction, loss of mitochondrial integrity, enhanced ROS generation, autophagy, estrogen receptor β-transactivation and increased tubulin polymerization. In in-vivo efficacy studies in rodent model, these indole derivatives induced significant regression in mice mammary tumour on 21 days daily oral dose. Moreover, compounds 19 and 23 were safe in Swiss albino mice in safety studies. These diarylindoles may further be optimized for better efficacy.
乳腺癌是女性癌症死亡的第二大主要原因,具有显著的发病率和死亡率。本研究描述了吲哚衍生物的设计、合成和详细的药理学,这些衍生物对乳腺癌细胞表现出显著的广谱抗增殖活性。详细的机制评估证实了 G0/G1 期阻滞、细胞凋亡诱导、线粒体完整性丧失、ROS 生成增加、自噬、雌激素受体β转导和微管蛋白聚合的诱导。在啮齿动物模型的体内疗效研究中,这些吲哚衍生物在 21 天的每日口服剂量下诱导了小鼠乳腺肿瘤的显著消退。此外,在安全性研究中,化合物 19 和 23 在瑞士白化小鼠中是安全的。这些二芳基吲哚类化合物可能会进一步优化以提高疗效。